DURHAM, N.C., Jan. 4, 2012 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that Thomas P. Mathers, Chief Executive Officer, will present a corporate update and Phase 3 development overview for lasmiditan at Biotech Showcase 2012 in San Francisco, CA. Mr. Mathers’ presentation is scheduled for Tuesday, January 10, 2012 at 11:00 a.m. in the Stockton Room at the Parc 55 Wyndham Union Square Hotel. Mr. Mathers will highlight recent clinical and regulatory milestones achieved by CoLucid for lasmiditan.
The Company will also be speaking with potential partners during both the Biotech Showcase and the J.P. Morgan Healthcare Conference.
About Lasmiditan
Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies. Lasmiditan is a member of a novel chemical class called “ditans” and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal pathway. Lasmiditan does not interact with vasoconstrictor 5-HT1B receptors activated by triptans.
Five clinical studies have been successfully completed outside of the U.S., including a Phase 2b double blind placebo controlled oral dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study of 391 patients, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001). Separation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia. Importantly, because there were no drug-related cardiovascular adverse effects in the previous five clinical studies, CoLucid expects the pivotal Phase 3 studies to confirm that lasmiditan’s side effect profile is highly differentiated from triptans and ergot derivatives.
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company’s investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company’s pipeline includes lasmiditan, a novel treatment for migraine, and a conjugated stigmine platform that has generated a series of preclinical candidates for wake promotion (COL-204), chronic pain, Alzheimer’s disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.
SOURCE CoLucid Pharmaceuticals, Inc.
